COMMUNIQUÉS West-GlobeNewswire

Sanofi : Déclaration des transactions sur actions propres
28/08/2017
Reporting FR This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]
Novo Nordisk A/S - Share repurchase programme
28/08/2017
Bagsværd, Denmark, 28 August 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Interim Data on MobiusHD Presented at the European Society of Cardiology Shows Promise in the Treatment of Resistant Hypertension
28/08/2017
MOUNTAIN VIEW, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Vascular Dynamics, Inc., (VDI) a privately held medical device company developing novel solutions for the treatment of hypertension, today announced interim [...]
Shire plc : MYDAYIS(TM) (mixed salts of a single-entity amphetamine product), Shire's New Once-Daily ADHD Treatment, Now Available in the U.S.
28/08/2017
For U.S. Audiences Only MYDAYIS(TM) (mixed salts of a single-entity amphetamine product), Shire's New Once-Daily ADHD Treatment, Now Available in the U.S. Mydayis, which is now available in the U.S., demonstrated [...]
Medtronic Plans for Renal Denervation Pivotal Trial After New Study Shows Significant Blood Pressure Reductions
28/08/2017
Published Simultaneously in The Lancet , the Late-Breaking SPYRAL HTN-OFF MED Study at ESC Successfully Isolates RDN Treatment Effect to Show Compelling Efficacy and Safety of Hypertension Procedure DUBLIN and BARCELONA [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
28/08/2017
FIT Biotech Oy Company release August 28, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - June 30, 2017
28/08/2017
Message from the CEO IBT are currently in the completion stage of the phase II clinical trial (NCT02472769) and are concurrently working with preparations for a subsequent phase III clinical trial. The phase II clinical [...]
Sanofi completes the acquisition of Protein Sciences
28/08/2017
Sanofi completes the acquisition of Protein Sciences - An innovative quadrivalent influenza vaccine will complement Sanofi Pasteur vaccine portfolio - Paris, France - August 28, 2017 - Sanofi announced today that it has [...]
Sanofi finalise l'acquisition de Protein Sciences
28/08/2017
Sanofi finalise l'acquisition de Protein Sciences - Un vaccin antigrippal quadrivalent innovant viendra compléter la gamme de vaccins de Sanofi Pasteur - Paris, France - Le 28 août 2017 - Sanofi annonce aujourd'hui [...]
Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
28/08/2017
1. Settlement of vested restricted stock units ("RSUs") Robert Burns, member of the board of directors of Targovax ASA (the "Primary Insider"), has on 25 August 2017 subscribed for 40,984 shares in Targovax ASA at a [...]
Santhera to Publish First Half-Year Report and Corporate Update on September 5, 2017
28/08/2017
Liestal, Switzerland, August 28, 2017 - Santhera Pharmaceuticals (SIX: SANN) will publish its 2017 first half-year report and corporate update on Tuesday, September 5, 2017 at 07:00 CET. An investor conference call with [...]
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
27/08/2017
Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard [...]
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
27/08/2017
Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III [...]
Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2018
25/08/2017
DUBLIN - August 25, 2017 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2018 second quarter cash dividend of $0.46 per ordinary share, representing a 7 percent increase over the [...]
Centre for Aging + Brain Health Innovation announces up to $3 million in funding available to support industry innovations in the field of aging and brain health
25/08/2017
TORONTO, Aug. 25, 2017 (GLOBE NEWSWIRE) -- The Centre for Aging + Brain Health Innovation (CABHI) announced today the second round of funding available through its Industry Innovation Partnership Program (I 2 P 2 ). [...]
Victoza® approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events
25/08/2017
Bagsværd, Denmark, 25 August 2017 - The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza ® (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events in adults with [...]
Summit Therapeutics plc : Notice of Results
25/08/2017
Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER AND HALF YEAR ENDED 31 JULY 2017 ON 31 AUGUST 2017 Oxford, UK, · August 2017 - Summit [...]
Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With Janssen
25/08/2017
Proceeds from amended agreement, combined with finances raised from recent public stock offering and current financial resources, significantly extend Minerva cash runway Combined proceeds are expected to support [...]
Zealand grants new warrants under employee warrant program
25/08/2017
Company announcement - No. 41/2017 Zealand grants new warrants under employee warrant program Copenhagen, August 25, 2017 - Zealand announces the grant of warrants to the Company's President and CEO Britt Meelby Jensen [...]

Pages